With empagliflozin, we now have evidence that another treatment for patients with heart failure with preserved ejection fraction (HFpEF) is possible, said Stefan Anker, MD, PhD, FESC, professor of cardiology, Department of Cardiology, Charité Campus Virchow Clinic, Berlin, Germany, and principal investigator of the EMPEROR-Preserved study.
With empagliflozin, we now have evidence that another treatment for patients with heart failure with preserved ejection fraction is possible, beyond renin–angiotensin–aldosterone inhibitors (RAASi), beta-blockers, and mineralocorticoid receptor antagonists (MRAs), said Stefan Anker, MD, PhD, FESC, professor of cardiology, Department of Cardiology, Charité Campus Virchow Clinic, Berlin, Germany, and principal investigator of the EMPEROR-Preserved study, which is investigating outcomes in patients with heart failure with preserved ejection fraction who may or may not have comorbid diabetes.
Transcript
How do you contrast the EMPEROR-Preserved results with findings from previous trials?
Thank you so much for this question. It's important to really understand what other trials have done, looking at combined end points with cardiovascular mortality and heart failure hospitalization in slightly varying combinations.
Over the last 16 years, we had 5 big trial programs looking into this in heart failure with preserved ejection fraction. They used slightly different definitions of the inclusion criteria, and basically different follow-up times, but always between 2000 and 6000 patients were included. Overall, the results never reached a convincingly significant level, with the best P value of around about 0.05 or 0.06 and around about 5% to 14% reduction in these end points. We know that maybe things went in the right direction, but not to a clinically meaningful and statistically really convincing degree.
The differences between the trial programs—apart from the design—are all these other therapies are targeting the RAASi system. Empagliflozin does not target the RAASi system. And of course, when you look into the baseline therapy—also in our trial—quite many HFpEF patients are already treated with beta-blockers, RAASi therapies, MRAs. So trying to achieve significance on top of that is difficult.
In one way, these other trials were not positive from a statistical sense, but we already practiced that kind of medicine anyway. But now we have the evidence that, really, we need to bring a new therapy on board for all of these patients, with empagliflozin, which is a metabolically active drug that targets a variety of different pathways. Maybe together, we can get the most for the patients.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More